NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: LIXTE Biotechnology's Expanded Ovarian Cancer Trial with MD Anderson and GSK
TL;DR
LIXTE Biotechnology expands its clinical trial with MD Anderson and GSK, potentially gaining a competitive edge in ovarian cancer treatment through its proprietary compound LB-100.
The trial adds Northwestern University as a second site, doubling enrollment to 42 patients and expects initial cohort data in the first half of 2026.
This expansion could improve outcomes for ovarian clear cell cancer patients by enhancing combination therapies and advancing new treatment paradigms.
LIXTE's LB-100 represents a pioneering approach in cancer biology called activation lethality, potentially revolutionizing how we treat this specific cancer type.
Found this article helpful?
Share it with your network and spread the knowledge!
LIXTE Biotechnology Holdings announced the expansion of its clinical trial collaboration with MD Anderson Cancer Center and GSK, adding a second site at Northwestern University's Robert H. Lurie Comprehensive Cancer Center and doubling patient enrollment from 21 to 42 patients.
The trial is evaluating LIXTE's proprietary compound LB-100 (a first-in-class PP2A inhibitor) in combination with GSK's Dostarlimab for the treatment of ovarian clear cell cancer.
The collaboration involves LIXTE Biotechnology Holdings, The University of Texas MD Anderson Cancer Center, pharmaceutical manufacturer GSK, and now the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
The trial is led by Amir Jazaeri, MD at MD Anderson, with the new Northwestern University site directed by Emily M. Hinchcliff, MD, MPH.
The trial was initiated in January 2024, and data from the initial cohort is expected to be presented in the first half of 2026.
LB-100 is LIXTE's first-in-class lead clinical PP2A inhibitor that represents a pioneering effort in activation lethality, a new field of cancer biology. It has demonstrated potential to enhance chemotherapies and immunotherapies and improve cancer patient outcomes.
Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
Additional information about LIXTE can be found at https://lixte.com/, and the full press release is available at https://ibn.fm/g1b2t.
Activation lethality is an entirely new field of cancer biology that LIXTE is pioneering, representing a new treatment paradigm for cancer therapy that is covered by a comprehensive patent portfolio.
The forward-looking statements involve risks and uncertainties that may cause actual results to differ materially, and undue reliance should not be placed on them for investment decisions. These risks are detailed in the company's SEC filings.
Curated from NewMediaWire
